Castle Biosciences (CSTL) Q3 FY2026 earnings: revenue $103 million, up 23.9% on the year
Castle Biosciences Inc. (CSTL) reported revenue of $103 million for Q3 FY2026, the quarter ended 30 September 2026, up 23.9% on the same quarter a year earlier. Net income was -$4 million, and diluted earnings per share $-0.13. The figures are the company's own, from the 10-Q it filed with the SEC on 5 November 2026.
Revenue
$103 million
+23.9% on the year · -0.6% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
-2.7%
-8.2% a year earlier
Q4 FY2024Q3 FY2026
Net income
-$4 million
Q4 FY2024Q3 FY2026
Diluted EPS
-$0.13
Q4 FY2024Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
What management said
Guidance figures: 1 raised.
Revenue rose 24% on the year: Third-quarter revenue was $102.9 million, against $83.0 million in the same quarter of 2025. Adjusted revenues, which exclude prior-period test report adjustments, were $101.9 million, against $80.5 million.
TissueCypher named key growth contributor: Management called TissueCypher a key contributor to top-line performance. Core revenue driver test reports, DecisionDx-Melanoma and TissueCypher combined, rose 22% against the prior-year quarter.
Adjusted EBITDA rose in the quarter: Nine-month Adjusted EBITDA was $20.0 million, down from $32.5 million a year earlier. Nine-month net loss was $20.7 million, against $21.8 million in the prior-year period.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
19.7
15.2
22.6
+29.9%
-12.8%
Capital expenditure
7.5
8.7
14.8
-13.4%
-49.5%
Free cash flow
12.2
6.6
7.8
+87.0%
+57.1%
Free cash flow margin
11.9%
6.3%
9.4%
Cash from investing
-4.7
-16.0
-18.4
Cash from financing
0.9
-0.9
-0.9
Depreciation and amortisation
4.2
4.1
3.8
+2.7%
+9.5%
Share-based compensation
11.2
11.6
12.1
-3.1%
-7.2%
Diluted shares, weighted
31m
30m
29m
+0.8%
+5.4%
Shares outstanding at period end
31m
31m
29m
+0.9%
+5.5%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
478
470
467
+1.8%
+2.4%
Debt
10.1
10.1
10.0
+0.1%
+0.3%
Operating lease liabilities
24.6
24.9
25.3
-1.1%
-2.7%
Finance lease liabilities
0.2
0.3
0.3
-10.2%
-30.1%
Other liabilities
66.0
55.9
60.0
+18.1%
+10.0%
Total liabilities and equity
579
561
563
+3.2%
+3.0%
Goodwill
10.7
10.7
10.7
0.0%
0.0%
Intangible assets
80.8
84.4
91.2
-4.3%
-11.4%
Investments
200
205
202
-2.5%
-1.1%
Cash and equivalents
78.0
62.1
85.6
+25.6%
-8.8%
Receivables
52.1
48.3
49.5
+7.8%
+5.3%
Inventory
10.4
10.6
8.7
-1.9%
+20.0%
Other assets
148
140
115
+5.3%
+28.2%
Total assets
579
561
563
+3.2%
+3.0%
Questions
What was Castle Biosciences' revenue in Q3 FY2026?
Castle Biosciences (CSTL) reported revenue of $103 million for Q3 FY2026, the quarter ended 30 September 2026, up 23.9% on the same quarter a year earlier.
How much did Castle Biosciences earn in Q3 FY2026?
Net loss for Q3 FY2026 was $4 million, and the diluted loss per share $0.13.
When did Castle Biosciences report Q3 FY2026 results?
Castle Biosciences filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 5 November 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 5 November 2026: the filing.